Lista de obras - James Baker - Dominio Público Uruguay

A human tissue-based functional assay platform to evaluate the immune function impact of small molecule inhibitors that target the immune system

artículo científico publicado en 2017

A pharmacokinetic modeling approach to predict the contribution of active metabolites to human efficacious dose

artículo científico publicado en 2016

Carboxylesterase catalyzed 18O-labeling of carboxylic acid and its potential application in LC-MS/MS based quantification of drug metabolites

scientific article published on 31 May 2019

Design, synthesis and structure–activity relationships of (indo-3-yl) heterocyclic derivatives as agonists of the CB1 receptor. Discovery of a clinical candidate ⬇️

artículo científico publicado el 12 de febrero de 2011

Design, synthesis, and structure-activity relationship study of conformationally constrained analogs of indole-3-carboxamides as novel CB1 cannabinoid receptor agonists

artículo científico publicado en 2010

Design, synthesis, and structure-activity relationships of indole-3-heterocycles as agonists of the CB1 receptor

artículo científico publicado en 2010

Design, synthesis, and structure–activity relationship study of bicyclic piperazine analogs of indole-3-carboxamides as novel cannabinoid CB1 receptor agonists ⬇️

artículo científico publicado el 20 de octubre de 2010

Design, synthesis, and structure–activity relationships of indole-3-carboxamides as novel water soluble cannabinoid CB1 receptor agonists

Discovery and optimization of 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives as a novel class of selective cannabinoid CB2 receptor agonists

artículo científico publicado el 29 de septiembre de 2011

Discovery of 5-Amino-N-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Inhibitors of IRAK4.

artículo científico publicado en 2015

Discovery of potent and orally bioavailable heterocycle-based cannabinoid CB1 receptor agonists ⬇️

artículo científico publicado el 22 de enero de 2011

Identification and hit-to-lead optimization of a novel class of CB1 antagonists

artículo científico publicado en 2010

Identification and optimisation of novel sulfonamide, selective vasopressin V1B receptor antagonists

artículo científico publicado en 2011

Identification of N-(1H-pyrazol-4-yl)carboxamide inhibitors of interleukin-1 receptor associated kinase 4: Bicyclic core modifications

artículo científico publicado en 2015

Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammation

artículo científico publicado en 2017

Interpretation of in vitro metabolic stability studies for racemic mixtures

scientific article published on 19 July 2018

Low brain penetrant CB1 receptor agonists for the treatment of neuropathic pain

artículo científico publicado en 2012

Optimisation of pharmacokinetic properties to afford an orally bioavailable and selective V1A receptor antagonist ⬇️

artículo científico publicado el 30 de mayo de 2011

Pharmacokinetic optimisation of novel indole-2-carboxamide cannabinoid CB1 antagonists ⬇️

artículo científico publicado el 19 de febrero de 2011

Pharmacological characterization of novel water-soluble cannabinoids

artículo científico publicado en 2006

Synthesis and SAR studies of novel 2-(4-oxo-2-aryl-quinazolin-3(4H)-yl)acetamide vasopressin V1b receptor antagonists

scientific article published on 21 December 2010

Synthesis and SAR studies of novel 2-(6-aminomethylaryl-2-aryl-4-oxo-quinazolin-3(4H)-yl)acetamide Vasopressin V1b receptor antagonists ⬇️

artículo científico publicado el 13 de abril de 2011

The discovery of novel 8-azabicyclo[3.2.1]octan-3-yl)-3-(4-chlorophenyl) propanamides as vasopressin V1A receptor antagonists

artículo científico publicado en 2011

The discovery of novel indole-2-carboxamides as cannabinoid CB1 receptor antagonists ⬇️

artículo científico publicado el 26 de octubre de 2010

The potential influence of CO2, as an agent for euthanasia, on the pharmacokinetics of basic compounds in rodents

artículo científico publicado en 2007

Lista de obras de James Baker

A human tissue-based functional assay platform to evaluate the immune function impact of small molecule inhibitors that target the immune system

A pharmacokinetic modeling approach to predict the contribution of active metabolites to human efficacious dose

Carboxylesterase catalyzed 18O-labeling of carboxylic acid and its potential application in LC-MS/MS based quantification of drug metabolites

Design, synthesis and structure–activity relationships of (indo-3-yl) heterocyclic derivatives as agonists of the CB1 receptor. Discovery of a clinical candidate ⬇️

Design, synthesis, and structure-activity relationship study of conformationally constrained analogs of indole-3-carboxamides as novel CB1 cannabinoid receptor agonists

Design, synthesis, and structure-activity relationships of indole-3-heterocycles as agonists of the CB1 receptor

Design, synthesis, and structure–activity relationship study of bicyclic piperazine analogs of indole-3-carboxamides as novel cannabinoid CB1 receptor agonists ⬇️

Design, synthesis, and structure–activity relationships of indole-3-carboxamides as novel water soluble cannabinoid CB1 receptor agonists

Discovery and optimization of 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives as a novel class of selective cannabinoid CB2 receptor agonists

Discovery of 5-Amino-N-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Inhibitors of IRAK4.

Discovery of potent and orally bioavailable heterocycle-based cannabinoid CB1 receptor agonists ⬇️

Identification and hit-to-lead optimization of a novel class of CB1 antagonists

Identification and optimisation of novel sulfonamide, selective vasopressin V1B receptor antagonists

Identification of N-(1H-pyrazol-4-yl)carboxamide inhibitors of interleukin-1 receptor associated kinase 4: Bicyclic core modifications

Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammation

Interpretation of in vitro metabolic stability studies for racemic mixtures

Low brain penetrant CB1 receptor agonists for the treatment of neuropathic pain

Optimisation of pharmacokinetic properties to afford an orally bioavailable and selective V1A receptor antagonist ⬇️

Pharmacokinetic optimisation of novel indole-2-carboxamide cannabinoid CB1 antagonists ⬇️

Pharmacological characterization of novel water-soluble cannabinoids

Synthesis and SAR studies of novel 2-(4-oxo-2-aryl-quinazolin-3(4H)-yl)acetamide vasopressin V1b receptor antagonists

Synthesis and SAR studies of novel 2-(6-aminomethylaryl-2-aryl-4-oxo-quinazolin-3(4H)-yl)acetamide Vasopressin V1b receptor antagonists ⬇️

The discovery of novel 8-azabicyclo[3.2.1]octan-3-yl)-3-(4-chlorophenyl) propanamides as vasopressin V1A receptor antagonists

The discovery of novel indole-2-carboxamides as cannabinoid CB1 receptor antagonists ⬇️

The potential influence of CO2, as an agent for euthanasia, on the pharmacokinetics of basic compounds in rodents